Price T Rowe Associates Inc Alkermes Plc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,998,606 shares of ALKS stock, worth $365 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
12,998,606
Previous 11,012,312
18.04%
Holding current value
$365 Million
Previous $265 Million
37.09%
% of portfolio
0.04%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding ALKS
# of Institutions
364Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$817 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$533 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$355 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$258 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.65MShares$187 Million2.97% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.61B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...